<DOC>
	<DOCNO>NCT00871000</DOCNO>
	<brief_summary>This phase 3b study compare immunogenicity reactogenicity dTpa-IPV vaccine DTPa-IPV vaccine administer booster dose healthy child 5-6 year age receive three primary vaccination dose DTPa-based vaccine accord `` 3-5-11 '' month schedule recommend Italy . In study , MMRV vaccine also co-administered child .</brief_summary>
	<brief_title>Immunogenicity Safety Boostrix Polio Vaccine Booster Dose 5 6-year-old Children .</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>A male female child 5 6 year age time vaccination . Subjects receive complete 3dose vaccination DTPabased combined vaccine accord 3511 month schedule line recommendation Italy . Subjects receive first dose live attenuate measlesmumpsrubella vaccine second year life , line recommendation Italy . Subjects investigator believe parents/guardians comply requirement protocol enrol study . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccine dose . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Previous booster vaccination tetanus , diphtheria , pertussis and/or poliomyelitis since vaccination first two year life . Previous measles , mumps , rubella and/or varicella second dose vaccination . Known history diphtheria , tetanus , pertussis , poliomyelitis , measles , mumps , rubella and/or varicella disease . Known exposure measles , mumps , rubella and/or varicella within 30 day prior study start . Any confirm suspected immunosuppressive immunodeficiency condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Administration immunoglobulin and/or blood product within three month precede vaccination plan administration study period . Occurrence transient thrombocytopenia neurological complication follow early immunisation diphtheria and/or tetanus . Occurrence follow adverse event previous administration DTP vaccine : Hypersensitivity reaction component vaccine ; Encephalopathy unknown aetiology occur within 7 day follow previous vaccination pertussiscontaining vaccine ; Fever &gt; = 40°C within 48 hour vaccination , due another identifiable cause ; Collapse shocklike state within 48 hour vaccination ; Convulsions without fever , occur within 3 day vaccination . Residence household person high risk varicella The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : Current febrile illness axillary temperature ≥ 38.5 ºC moderate severe illness within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Boostrix Polio</keyword>
	<keyword>dTpa-IPV</keyword>
</DOC>